Entering text into the input field will update the search result below

Aimmune up 9% premarket on successful AR101 study

Mar. 25, 2019 8:22 AM ETAimmune Therapeutics, Inc. (AIMT) StockBy: Douglas W. House, SA News Editor16 Comments
  • Aimmune Therapeutics (NASDAQ:AIMT) is up 9% premarket on light volume in response to successful results from a European Phase 3 clinical trial, ARTEMIS, evaluating lead candidate AR101 for the treatment of peanut allergy.
  • The study met the primary endpoint of a statistically significant proportion of AR101-treated patients who tolerated a 1 g dose of peanut protein in a blinded exit challenge at month 9 compared to placebo (p<0.00001).
  • The median tolerated dose of peanut protein in the treatment group improved 100-fold (10 mg at baseline to 1,000 mg at exit).
  • No new safety signals were reported.
  • The company plans to file a marketing application in Europe mid-year. Its U.S. marketing application is currently under FDA review with an expected action date around January 2020.
  • Management will host a conference call this morning at 8:30 am to discuss the results.

Recommended For You

Related Stocks

SymbolLast Price% Chg
AIMT--
Aimmune Therapeutics, Inc.